New CAR-T battle plan tested against tough childhood leukemia
NCT ID NCT06343090
Summary
This study is testing two different CAR-T cell therapy strategies for children and young adults with B-cell acute lymphoblastic leukemia that has returned or not responded to standard treatments. One approach uses two types of engineered immune cells (CD19 and CD22 CAR-T) in sequence, while the other uses one type (CD19 CAR-T) followed by a stem cell transplant. The goal is to see which method better controls the disease and helps patients live longer without it coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Hospital
RECRUITINGBeijing, Beijing Municipality, 102206, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.